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GSK3β predicts survival in pancreatic cancer

INTRODUCTION
GSK3β is a protein kinase involved in the regulation of cell cycle, transcription, proliferation, differentiation and apoptosis. A number of key oncoproteins, including β-catenin, c-Myc, Cyclin D, Cyclin E, and c-Jun, are known substrates of GSK3β; most are functionally inhibited by it (1-3).
Wnt signaling is essential for the embryonic development of the exocrine pancreas (4, 5) and deregulation of this pathway has been linked to pancreatic ductal adenocarcinoma (PDAC) (6) . GSK3β is a well-characterized negative regulator of canonical Wnt signaling: it phosphorylates β-catenin, targeting it for degradation. Although mutations in pathway components such as β-catenin and APC are rare in PDAC (7, 8) , abnormal accumulation of β-catenin in the nucleus and cytoplasm have been described in a large fraction of pancreatic intraepithelial neoplasm (PanIN) lesions and PDAC (9) (10) (11) . In addition, genomic characterization revealed that 100% of patients with pancreatic cancer have aberrations of the Wnt or Notch pathways (12) . β-catenin aberrant localization is most pronounced in high-grade PanIN and invasive carcinoma (9) and its expression correlates with the degree of differentiation (13) . Wnt pathway activity has been shown to be increased in the majority of human PDAC samples and cell lines tested and inhibition of the pathway resulted in a reduction in cell proliferation and an increase in apoptosis (10) . Further, ataxia telangiectasia group D-associated protein (ATDC) mediated accumulation of β-catenin and activation of its target genes was shown to promote PDAC growth and metastasis (14) .
It has been previously shown that inhibition of GSK3β in a preclinical PDAC model causes stabilization and nuclear translocation of β-catenin, and induces poor differentiation, proliferation, and resistance to radiation (15) . To explore the potential utility of GSK3β as a prognostic biomarker of clinical outcomes, we examined its cytoplasmic expression in a tissue microarray (TMA) generated from patients enrolled in Radiation Therapy Oncology Group (RTOG) 9704, a prospective intergroup multicenter phase III trial of adjuvant chemotherapy and chemoradiation for resected PDAC (16) .
Research. 
PATIENITS AND METHODS
Patient population
The exploratory cohort consisted of a 38-sample TMA from patients who underwent pancreaticoduodenectomy at the University of Michigan. The samples were linked to a clinical database with complete details on patient population, tumor characteristics, treatment, and clinical outcomes. A full description of this cohort has been previously published (17) . Immunohistochemical peroxidase staining with a GSK3β antibody (Abcam, Cambridge, MA) was performed. Stained slides were scored by a gastrointestinal pathologist using a three-tier system (none, low and high). 
GSK3β assay
Automated Quantitative Immunofluorescence Analysis (AQUA) was conducted as described by Camp et al. (18) .
AQUA is a method of determining protein levels based on automated quantification of fluorescence intensity in targets of interest. Briefly, slides were stained for cytokeratin 8 (Novus Biologicals, Littleton, CO, NBP1-04926, 1:1000) and GSK3β (AbCam, Cambridge, MA, AB31826, clone M131, 1:600). The optimization of antibody concentrations and other conditions was performed as described by Bordeaux (19) and Dolled-Filhart (20 antibodies were extensively validated using IHC on several different University of Michigan TMAs (a multi-tumor TMA, a breast cancer TMA, a pancreatic TMA, a urological TMA and a TMA of normal tissues). A pathologist (DT) verified that the fluorescent stain was done properly, and that the cytokeratin stain was correctly staining the carcinoma cells.
Images of each core were captured with a microscope at 3 different extinction/emission wavelengths. Within each tumor core, areas of tumor were distinguished from stroma and necrotic areas by the cytokeratin stain (an epithelial marker). The pixel intensity of the GSK3β protein/antibody complex was then machine-read and reported. GSK3β was read only within the tumor-specific mask. An example of the GSK3β stain in one patient is depicted in Figure 1 . Cores that did not pass the quality-assurance checks in the software were excluded from scoring. Each patient's tumor in the TMA was represented by two cores, and results were averaged, providing a better assessment of the degree of GSK3β staining within the tumor of each patient.
Statistical Analysis
Overall survival (OS) was calculated from date of randomization to date of death due to any cause or last followup for censored patients. Disease-free survival (DFS) events were defined as local, regional or distant relapse, appearance of a second primary lesion or death due to any cause. DFS was calculated from date of randomization to date of first documented failure or last follow-up for censored patients. OS and DFS were estimated univariately with the Kaplan-Meier method (21) .
Based on the findings in the exploratory cohort, GSK3β was categorized using its upper quartile as a cut point.
Although the exploratory cohort had three categories of GSK3β expression, only approximately one quarter of patients were in the highest expression category. For this reason, to more closely approximate how the analysis was done in the exploratory cohort, patients in the upper quartile (>Q3) were compared to patients in the lower three quartiles (≤Q3) in the test cohort.
Research. GSK3β groupings were compared using the log-rank test. Potential associations between baseline characteristics and GSK3β groupings were carried out using the chi-square or Fisher's exact test.
Univariate and multivariate Cox proportional hazards models (22) were used to determine if there are any associations of GSK3β with OS and DFS. For the multivariable analysis, only GSK3β was forced into the models and a backwards selection procedure was used to choose other variables using α ≥ 0.05 level as the exit criteria for the model building. The following variables were assessed in the models along with GSK3β: treatment arm, age, gender, race, primary tumor location, nodal status (stratification variable), largest tumor dimension (stratification variable), and surgical margin status (stratification variable). The following baseline characteristics were dichotomized: pathological T-stage (T1, T2 vs. T3, T4) and AJCC stage (I, II vs. III, IV). Race was categorized as White vs. African American/other. The proportional hazards assumption was evaluated by graphing the log(-log(survival)) vs. log of survival time for the GSK3β groupings, which should result in parallel curves.
RESULTS
Exploratory cohort
Based on preclinical data generated at the University of Michigan, GSK3β was first tested for its prognostic value in an exploratory dataset of a group of patients treated at the University of Michigan with chemotherapy and chemoradiation after resection of their pancreatic cancer (17) . It was hypothesized that, as a negative regulator of Wnt, substantial expression would be required for it to exert an effect. The analysis revealed a trend towards improved progression-free survival (PFS) when all three groups were compared to each other ( Figure S1A ). Since the outcome of patients with no-and low GSK3β expression was not statistically different, these two groups were combined into one. Comparing this new low expression group to the original group of high expression revealed a statistically significant difference in PFS in favor of high GSK3β expression ( Figure S1B ). The estimated 3-year PFS rates were 16.7% and 66.7% in the high and low GSK3β groups, respectively. To validate these findings, in order to detect a difference between 20% and 60% 3-year PFS, using a two-sided test with α <0.05 and 90% power, a minimum of 30 patients per expression group would be required.
Test cohort
GSK3β was then assayed in a TMA from 199 eligible patients treated on RTOG 9704. Of these, 36 patients failed the AQUA quality test and were excluded from analysis. The remaining 163 eligible and analyzable patients form the test cohort. This number exceeded the minimal sample size calculated based on the exploratory analysis. The distribution of GSK3β in this cohort by treatment arm is shown in Table S1 .
To ensure that the test cohort is a representative sample of patients treated on RTOG 9704, we tested for differences in baseline characteristics of the 163 eligible and GSK3β-analyzable cases and all other eligible cases on the trial. There were no statistically significant differences. Similarly, baseline characteristics were not significantly different among patients in the upper quartile (>Q3 ) and lower three quartiles (≤Q3) for GSK3β expression (Table 1) . We also tested the proportional hazards assumption. While it was not fully met (as is usually the case), the curves for assessing this assumption were roughly parallel, making reporting the hazard ratios (HR) still appropriate.
The 3-yr. OS rates for GSK3β ≤Q3 vs. GSK3β >Q3 were 16% (95% CI: 10%-23%) and 30% (95% CI: 17%-44%), respectively [log rank p-value=0.0082 (Figure 2a )]. Table 2 The 3-yr. DFS rates for those with GSK3β ≤Q3 and GSK3β >Q3, were 9% (95% CI: 5%-15%) and 20% (95% CI: 9%-33%) respectively [log-rank p-value =0.0081 (Figure 2b )]. Potential correlations between GSK3β expression and CA19-9 and tumor grade were tested. There were no statistically significant correlations.
Since CA-19-9, a known prognostic factor in PDAC, was not available for all patients, separate multivariable analyses for OS and DFS in all patients and in patients with CA-19-9 were conducted. Table 3 were significantly associated with OS. Table S2 shows the multivariable Cox proportional hazards model of OS for all 163 patients, including those who did not have pre-treatment CA19-9. GSK3β was a significant predictor of OS in the final model as well. Table 4 shows the multivariable Cox model of DFS in patients with CA19-9. GSK3β expression had a borderlinesignificant association with DFS, with a HR of 0.65 (95% CI: 0.98, 1.07; p-value=0.092) while surgical margins and CA-19-9 were statistically significant. Table S3 shows the multivariable Cox model of DFS in all patients. In this model, GSK3β was the only factor that was statistically significant.
To determine if GSK3β is a prognostic factor or predictive of chemotherapy benefit in PDAC, the analyses above were also conducted within each treatment arm separately (i.e. 5-FU or gemcitabine based treatment arms).
There were no significant differences in the observed effects by treatment arm, indicating that GSK3β is not a predictive biomarker for either 5-FU or gemcitabine based therapies.
DISCUSSION
The main finding in this study is that GSK3β is an important independent prognostic factor in PDAC. We noted markedly superior survival and disease-free survival (8.8 and 6.8 months improvement in median, respectively) in 
distinct subgroups of patients with widely varying prognosis and clinical outcomes. These differences were clinically meaningful, essentially doubling of overall survival and DFS in high expressors. By comparison, the addition of erlotinib to gemcitabine in patients with metastatic pancreatic cancer in the NCIC trial resulted in a hazard ratio of 0.82, a statistically significant difference prompting FDA approval, but clinically not meaningfulan increase of only two weeks in median survival (23) .
Biologically, GSK3β is a negative regulator of β-catenin; it is part of a complex that ubiquitinates β-catenin, thereby tagging it for proteasomal degradation. β-catenin is an oncogenic transcription factor that has been linked to numerous processes that drive carcinogenesis, differentiation, tumor growth and metastasis. However, age, sex, performance status, socioeconomic status, ethnicity, tumor markers (CA-19-9 and CEA), location within the pancreas, tumor size, extent, grade, differentiation, perineural and blood/lymph vessel invasion, and lymph node status. Tumor diameter, lymph node status, differentiation, negative resection margins (24, 25) and CA-19-9 (26) seem to be the most important factors, although there is substantial disagreement between studies. In RTOG 9704, the study from which our samples were obtained, only nodal involvement and CA-19-9 have been previously shown to have a statistically significant independent effect on survival. We now show that GSK3β is an additional independent factor in that dataset. It is worth noting that the backwards selection multivariable modeling did not include nodal status in the final model, as the modeling algorithm frequently selected nodal status for exit. However, the final models did include CA 19-9 (Tables 3 and 4) suggesting that the predictive power of GSK3β exceeds that of nodal status, but is only additive to that of CA-19-9. Also, although the proportional hazards assumption was not fully met, it is robust. In this regard, our data is not different from data reported from most clinical trials. It is important to keep in mind that each reported HR represents an average effect over the range of times observed.
In addition to the clinical and pathological factors discussed above, a large number of molecular biomarkers have been examined with inconsistent findings. In a recent meta-analysis, vascular endothelial growth factor (VEGF), Bcl-2, bax, and p16 were found to be significant prognostic factors; p53, smad4 and EGFR were not (27) . 1-3) and it is possible that GSK3β influences outcome through regulation of multiple pathways. It is also possible that the effects of GSK3β in the cytoplasm are different than they are in the nucleus, as suggested by Ougolkov's report (28) . In future work, cytoplasmic and nuclear GSK3β expression and their associations with outcomes should be assessed. It is also interesting to note that the other GSK3 isoform, GSK3α, may have an opposite effect in pancreatic cancer (34, 35) .
This may have significant implications in the development of specific inhibitors targeting GSK3 or the Wnt-β-catenin pathways for therapy. Taken together with preclinical data, our findings also raise the question of GSK3β can serve as a prognostic biomarker is important in the setting of personalized therapy for pancreatic cancer, and GSK3β expression should be considered for stratification in future clinical trials. Overall survival (A) and Disease-free survival (B) by GSK3β expression. The 3-yr. OS rates for GSK3β ≤Q3 vs. GSK3β > Q3 were 16% (95% CI: 10%-23%) and 30% (95% CI: 17%-44%), respectively [log rank p-value=0.0082]. The 3-yr.
DFS rates for those with GSK3β ≤Q3 and GSK3β >Q3, were 9% (95% CI: 5%-15%) and 20% (95% CI: 9%-33%) respectively [log-rank p-value =0.0081].
